Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT05123443

Longitudinal Assessment of Iron Rims in MS Lesions

Longitudinal Assessment of Iron Rims in MS Lesions — Recruiting • Neurology • NCT05123443.

📅 25 Mar 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05123443
Sponsor
Nottingham University Hospitals NHS Trust
Start
2022-09-03
ClinicaliQ Trial Snapshot
  • Longitudinal Assessment of Iron Rims in MS Lesions — Recruiting • Neurology • NCT05123443.
  • In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course. Iron rim lesions can be detected through their appearance on susceptibility-based brain MRI at either 3-Tesla or….
  • Sponsor: Nottingham University Hospitals NHS Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course. Iron rim lesions can be detected through their appearance on susceptibility-based brain MRI at either 3-Tesla or 7-Tesla strength. We know that the formation of chronic active lesions is not uniform across MS cohorts so identifying risk factors which predispose individuals to the formation of rim lesions may provide a useful biomarker for clinical progression. One candidate set of risk factors include genetic variants which…

Eligibility Snapshot
  • : * Men and women aged above 16 years * Clinical diagnosis of MS as per revised McDonald Criteria 2017 * Existing susceptibility-weighted brain MRI scan * Able to provide blood samples

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug
Neurology · BBC Health · 04 Mar 2026
Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant…
View brief →
Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Guideline
Headaches in Over 12s: Diagnosis and Management (NICE CG150)
Neurology · 27 Mar 2026
Take a focused history documenting headache onset, frequency, duration, severity, associated symptoms, and functional impact to distinguish primary headaches from secondary causes…
View guideline →
Guideline
Multiple Sclerosis in Adults: Management (NICE NG220)
Neurology · 27 Mar 2026
Initiate disease-modifying therapy (DMT) in all adults with relapsing-remitting MS immediately upon diagnosis using first-line agents (interferon beta, glatiramer acetate, or teriflunomide),…
View guideline →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
My daughter has childhood dementia and may not live past 16
Neurology · BBC Health · 01 Apr 2026
Key Clinical Takeaways Childhood dementia represents a group of rare progressive neurodegenerative disorders with devastating outcomes—Sophia's case illustrates the severe functional decline…
View brief →